Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.04 – $0.12
43% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $16.9M | $43.9M | $54.6M | $39.3M | $89.3M | $60.1M | $79.7M | $102.5M |
| Cost of revenue | $15.2M | $35.3M | $48.0M | $50.0M | $63.1M | $71.8M | $41.0M | $53.5M |
| Gross profit | $1.7M | $8.6M | $6.6M | −$10.7M | $26.2M | −$11.7M | $38.7M | $49.1M |
| Gross margin | 9.9% | 19.6% | 12.1% | -27.2% | 29.4% | -19.4% | 48.6% | 47.8% |
| R&D | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating income | −$9.4M | −$29.6M | −$15.1M | −$31.7M | −$10.5M | −$75.6M | −$20.6M | $4.5M |
| EBITDA | −$66.0M | −$33.5M | −$10.8M | −$73.0M | −$7.8M | −$104.3M | −$19.4M | $4.9M |
| Net income | −$64.7M | −$35.5M | −$7.8M | −$74.7M | −$11.4M | −$108.4M | −$21.0M | $5.5M |
| Net margin | -382.5% | -80.9% | -14.2% | -190.1% | -12.7% | -180.3% | -26.3% | 5.4% |
| EPS (diluted) | -0.20 | -0.08 | -0.01 | -0.12 | -0.02 | -0.15 | -0.03 | 0.01 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $111M | $-0.00 | $-0.00–$-0.00 | 1 |
| 2027 | $128M | $0.00 | $0.00–$0.00 | 1 |
| 2028 | $145M | $0.01 | $0.01–$0.01 | 1 |
Forward consensus · source: Financial Modeling Prep
BUBS AUSTRALIA LTD
No one on the platform currently holds BUBSF.
No tracked institution reports a position in BUBSF as of their last filing.
No one on the platform has traded BUBSF yet.
| $64M |
| — |
| NBBTFNatural Beauty Bio-Technology Limited | $0.06 | +0.00% | $122M | — |
| NWINFNaked Wines plc | $0.94 | +0.00% | $63M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 0.3× sales vs its 1.6× historical median P/S.
Fair value ≈ $0.39 · price $0.08 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.